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Tregs constitute a subset of CD4 + T cells whose role, in simple terms, is to suppress (or regulate) immune inflammatory function. Until the discovery of Foxp3 as the transcription factor determining Treg identity, 9 investigators focused on CD25, the high-affinity receptor for interleukin-2 (IL-2), as a defining feature of these cells. Ontogenic and functional studies have identified thymus-derived naturally occurring Tregs as Foxp3 + cells that circulate in the blood in low numbers in the steady state, as well as induced Tregs that arise from mature T-cell subsets during certain situations, such as tolerance induction, producing large amounts of the cytokine IL-10. 10 Treg's suppressive function has been known for years and represents a double-edged sword. On the one hand, in conditions such as allergy and autoimmune disease, harnessing the regulatory ability of T cells can be beneficial and therapeutically desirable. On the other, in conditions such as cancer, where tumor cell eradication is the goal, Tregs are an obstacle to effective immunotherapy.
Previous work from the same and other groups had indicated that T 11, 12 and B 13 lymphocytes participate in the response to MI. Although Tregs have received attention in other areas of cardiovascular disease, 14 their role in the biphasic monocyte/macrophage response that follows MI has remained unknown. In the current article, Weirather et al 8 demonstrate the expansion of Tregs in the mediastinal lymph nodes draining the heart and in the infarct itself. On day 7 after coronary ligation, ≈150 Tregs accumulate per mg infarct tissue which, compared with the ≈50 000 macrophages accumulating per mg infarct tissue, 5, 15 represents a small Treg:macrophage ratio. This clearly eliminates Tregs as foot soldiers of the response. However, even a small number of leukocytes can be important. The question then is, does this accumulation matter?
Weirather et al 8 induced MI in Foxp3 DTR mice, which allowed the investigators to deplete Tregs. In these mice, infarct size was increased, resolution of infarct inflammation was impaired, and neutrophil and Ly6C high monocyte numbers were augmented. Moreover, the gene expression profile from macrophages isolated from 5-day-old infarcts was biased toward inflammation, and factors typically associated with healing, such as transforming growth factor-β, osteopontin, and transglutaminase factor XIII, were decreased. The latter was previously identified as a prominent marker of inflammatory classical mouse monocytes by the ImmGen consortium (www.immgen.org), highlighting that the simple M1/M2 categorization of macrophages is far from precise, and suggesting that local factors may change specific genes in a manner that overrides the M1/M2 classification. Taken together, absence of Tregs led to impaired transition toward resolution of inflammation, resulting in the persistence of inflammatory macrophages and delayed healing (Figure) .
When Tregs were depleted with a CD25 antibody 8 days before MI, post-MI survival was impaired, which did not occur in Foxp3 DTR mice. However, antibody depletion led to more numerous neutrophil and Ly6C high monocyte in infarcts. Treatment with a superagonistic anti-CD28 antibody expanded Tregs 2-fold in blood and heart-draining lymph nodes,
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shifted the macrophage gene expression toward inflammation resolution, improved infarct matrix repair, and reduced infarct mortality. Coculture experiments suggested that Tregs may modulate macrophage phenotype in vitro via secretion of IL-10 and IL-13. Collectively, the Frantz group describe an interesting observation in 2 different models of Treg depletion and 1 model of Treg activation: an altered abundance of these cells correlated with an altered macrophage phenotype and outcome post-MI. The study adds to the increasing evidence that heart macrophages are important in the evolution of heart failure, and reports a novel, potentially clinically important mechanism of how cardiac macrophage phenotype is steered. The data raise several interesting questions. For example, where and how do Tregs interact with myeloid cells? On the one hand, recent studies indicate that IL-10 is a critical homeostatic factor for macrophages. 16 On the other hand, the low absolute numbers of Tregs vis-a-vis myeloid cells in the infarct raises the question of whether additional interactions are important elsewhere. Can Tregs influence the supply of cells in other locations? Previously, Tregs were shown to influence the action of hematopoietic progenitors in the bone marrow. 17 Can Tregs interact with monocyte progenitors and change their phenotype before they enter inflamed tissues? Recent studies have shown that cell intrinsic factors, such as the orphan nuclear hormone receptor, nuclear receptor subfamily 4, group a, member 1 (Nr4a1) expressed in monocytes regulate the emergence of Ly6C low monocytes in blood and regulate the infarct macrophage phenotype. 4, 18 Another regulator of macrophage phenotype after MI is the master transcription factor IRF5 (interferon regulatory factor 5). 19 In light of the Treg data discussed above, it would be interesting to explore whether these mechanisms are coupled or independent. Overall, it is likely that the infarct macrophage phenotype results from an integration of multiple inputs, including cellintrinsic, systemic, and local factors. Going forward, we will need to identify viable avenues for a therapeutic intervention that modulates infarct inflammation and prevents post-MI heart failure. Additional work will show whether Treg activation is such an option for patients with MI.
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